Home

lantaani Edessäsi Jauhaa ac psma valon pakattu ahdas

Ac-225 PSMA therapy
Ac-225 PSMA therapy

a-c PSMA ligands composed of a glutamine-urea-lysine PSMA-binding... |  Download Scientific Diagram
a-c PSMA ligands composed of a glutamine-urea-lysine PSMA-binding... | Download Scientific Diagram

Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a  game changer in nuclear medicine. | Semantic Scholar
Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine. | Semantic Scholar

A) 68 Ga-PSMA-11 PET/CT scan of patient with pretherapeutic tumor... |  Download Scientific Diagram
A) 68 Ga-PSMA-11 PET/CT scan of patient with pretherapeutic tumor... | Download Scientific Diagram

Lu-177 PSMA therapy vs Ac-225 PSMA therapy
Lu-177 PSMA therapy vs Ac-225 PSMA therapy

PSMAtreatment - What is actinium PSMA - PSMA Forum
PSMAtreatment - What is actinium PSMA - PSMA Forum

Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with  [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer |  Journal of Nuclear Medicine
Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine

Frontiers | Current role of prostate-specific membrane antigen-based  imaging and radioligand therapy in castration-resistant prostate cancer
Frontiers | Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer

Frontiers | Incorporating PSMA-Targeting Theranostics Into Personalized  Prostate Cancer Treatment: a Multidisciplinary Perspective
Frontiers | Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective

Prostate-specific Membrane Antigen PET: Therapy Response Assessment in  Metastatic Prostate Cancer | RadioGraphics
Prostate-specific Membrane Antigen PET: Therapy Response Assessment in Metastatic Prostate Cancer | RadioGraphics

ProsTIC/PCF Global Webinar 2023: 225-Actinium-PSMA-617: Data and  Perspectives from a Medical Oncologist
ProsTIC/PCF Global Webinar 2023: 225-Actinium-PSMA-617: Data and Perspectives from a Medical Oncologist

mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post–Androgen  Deprivation Therapy Setting: Response to Treatment and Survival Analysis |  Journal of Nuclear Medicine
mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post–Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis | Journal of Nuclear Medicine

Development of Novel 111In/225Ac-Labeled Agent Targeting PSMA for Highly  Efficient Cancer Radiotheranostics | Journal of Medicinal Chemistry
Development of Novel 111In/225Ac-Labeled Agent Targeting PSMA for Highly Efficient Cancer Radiotheranostics | Journal of Medicinal Chemistry

Cancers | Free Full-Text | PSMA Theranostics: Science and Practice
Cancers | Free Full-Text | PSMA Theranostics: Science and Practice

Safety and Activity of Alpha-Emitting Ac-225-PSMA-617 Radioligand Therapy  in mCRPC That Has Progressed After Lu-177-PSMA, Journal Club – Christopher  Wallis & Zachary Klaassen
Safety and Activity of Alpha-Emitting Ac-225-PSMA-617 Radioligand Therapy in mCRPC That Has Progressed After Lu-177-PSMA, Journal Club – Christopher Wallis & Zachary Klaassen

Structural formula of [ 225 Ac]Ac-PSMA-I&T, with DOTAGA as a chelator.... |  Download Scientific Diagram
Structural formula of [ 225 Ac]Ac-PSMA-I&T, with DOTAGA as a chelator.... | Download Scientific Diagram

Prof.Dr.LEVENT KABASAKAL | Ac-225-PSMA for Castration Resistant Metastatic  Prostate Cancer
Prof.Dr.LEVENT KABASAKAL | Ac-225-PSMA for Castration Resistant Metastatic Prostate Cancer

²²⁵Ac-PSMA-617 and ²²⁵Ac-PSMA-TO-1 mouse overall survival. A... | Download  Scientific Diagram
²²⁵Ac-PSMA-617 and ²²⁵Ac-PSMA-TO-1 mouse overall survival. A... | Download Scientific Diagram

Efficacy and safety of Ac-225-PSMA-617 TAT in Prostate Cancer - Oncidium  Foundation
Efficacy and safety of Ac-225-PSMA-617 TAT in Prostate Cancer - Oncidium Foundation

First clinical results for PSMA TAT using Ac-225-PSMA-I&T in advanced mCRPC  patients - Oncidium Foundation
First clinical results for PSMA TAT using Ac-225-PSMA-I&T in advanced mCRPC patients - Oncidium Foundation

Clinical outcomes and molecular profiling of advanced metastatic  castration-resistant prostate cancer patients treated with 225Ac-PSMA-617  targeted alpha-radiation therapy - ScienceDirect
Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy - ScienceDirect

Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic  castration-resistant Prostate Cancer patients
Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients

⁶⁸Ga-PSMA-11 PET/CT scans of a representative patient with mCRPC after... |  Download Scientific Diagram
⁶⁸Ga-PSMA-11 PET/CT scans of a representative patient with mCRPC after... | Download Scientific Diagram

Global experience with PSMA-based alpha therapy in prostate cancer |  European Journal of Nuclear Medicine and Molecular Imaging
Global experience with PSMA-based alpha therapy in prostate cancer | European Journal of Nuclear Medicine and Molecular Imaging